Section Arrow
MDWD.NASDAQ
- MediWound Ltd
Quotes are at least 15-min delayed:2025/07/21 06:30 EDT
Pre Market
Last
 --
-- (--)
Bid
20
Ask
23
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 20.46
+0.41 (+2.04%)
Day High 
21.03 
Prev. Close
20.05 
1-M High
21.255 
Volume 
77.90K 
Bid
20
Ask
23
Day Low
20.1 
Open
20.24 
1-M Low
18.5 
Market Cap 
216.69M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 20.03 
20-SMA 19.66 
50-SMA 20.06 
52-W High 22.505 
52-W Low 14.14 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.05/-2.20
Enterprise Value
223.21M
Balance Sheet
Book Value Per Share
2.89
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
20.22M
Operating Revenue Per Share
2.41
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2.01 -0.27 -11.84%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.515 -0.56 -3.98%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.155 +0.315 +5.39%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.03 +0.11 +1.86%
Quotes are at least 15-min delayed:2025/07/21 06:30 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.